Literature DB >> 17467926

Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation.

Nuran Senel Bese1, Jolyon Hendry, Branislav Jeremic.   

Abstract

The prescribed total radiation dose should be administered within a specific time. In daily clinical practice, however, unplanned treatment interruptions resulting in prolongation of the overall treatment time are predictable. The present review evaluated the existing published data regarding the affect of the prolongation of the overall treatment time on the tumor control rate and outcome of patients with head-and-neck, lung, and uterine cervical cancer and other treatment sites. In most studies, including the planned interruption (split-course) schedules, as well as the retrospective studies analyzing the role of overall treatment time, a detrimental effect from the treatment break on the outcome was evident. This is suggestive of the deleterious effect of accelerated repopulation of tumor clonogens. In particular for the cancers of the head and neck for which the evidence is the strongest for such a consequence, even a 1-day interruption resulted in a decrease in the local control rate by 1.4%. Although the increased number of gaps was associated with a negative outcome, the data are contradictory concerning the effect of the number of gaps. The main recommendation is to exert all efforts to retain the planned irradiation schedule; however, existing data have shown that interruptions that effect the programmed time-course for irradiation need to be compensated for. This is to ensure biologic equivalence in treatment efficacy compared with uninterrupted regimens with respect to cancer site and stage. Practical methods for compensation using radiobiologic modeling and their limitations are also discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17467926     DOI: 10.1016/j.ijrobp.2007.03.010

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  105 in total

Review 1.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

Review 2.  The role of radiotherapy in locally advanced pancreatic carcinoma.

Authors:  Ruchika Gutt; Stanley L Liauw; Ralph R Weichselbaum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

3.  Medical oncology: Chemoradiotherapy for NSCLC-does a 'standard' exist?

Authors:  Allen M Chen; Primo N Lara
Journal:  Nat Rev Clin Oncol       Date:  2010-11-23       Impact factor: 66.675

4.  The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.

Authors:  Rob Glynne-Jones; Maher Hadaki; Mark Harrison
Journal:  J Gastrointest Oncol       Date:  2013-09

5.  Short- and Long-term Opioid Use in Patients with Oral and Oropharynx Cancer.

Authors:  Jessica D McDermott; Megan Eguchi; William A Stokes; Arya Amini; Mohammad Hararah; Ding Ding; Allison Valentine; Cathy J Bradley; Sana D Karam
Journal:  Otolaryngol Head Neck Surg       Date:  2018-11-06       Impact factor: 3.497

6.  A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer.

Authors:  Tomoya Yokota; Satoshi Hamauchi; Yukio Yoshida; Takashi Yurikusa; Miho Suzuki; Aiko Yamashita; Hirofumi Ogawa; Tsuyoshi Onoe; Keita Mori; Tetsuro Onitsuka
Journal:  Support Care Cancer       Date:  2018-04-07       Impact factor: 3.603

7.  Effects of bone marrow or mesenchymal stem cell transplantation on oral mucositis (mouse) induced by fractionated irradiation.

Authors:  M Schmidt; J Haagen; R Noack; A Siegemund; P Gabriel; W Dörr
Journal:  Strahlenther Onkol       Date:  2014-01-24       Impact factor: 3.621

8.  The "rocky treatment course": identifying a high-risk subgroup of head and neck cancer patients for supportive interventions.

Authors:  Horia Vulpe; Janet Ellis; Shao Hui Huang; Eshetu G Atenafu; Raymond W Jang; Gary Rodin; Jolie Ringash
Journal:  Support Care Cancer       Date:  2016-11-04       Impact factor: 3.603

9.  Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy.

Authors:  Clayton B Hess; Dominique L Rash; Megan E Daly; D Gregory Farwell; John Bishop; Andrew T Vaughan; Machelle D Wilson; Allen M Chen
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-04       Impact factor: 6.223

10.  Caregiver-reported neuropsychiatric symptoms in patients undergoing treatment for head and neck cancer: a pilot study.

Authors:  Stewart M Bond; Deborah K Hawkins; Barbara A Murphy
Journal:  Cancer Nurs       Date:  2014 May-Jun       Impact factor: 2.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.